Do GLP-1 drugs shield you from tempting food ads? new study investigates
NCT ID NCT07505134
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether GLP-1 weight-loss medications reduce cravings and unhealthy food choices triggered by food advertisements. Fifty adults taking tirzepatide will view food or tech ads and report their cravings and food intake. The goal is to understand if these drugs make people less vulnerable to external food cues.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GLP-1 medication (tirzepatide)
- What this could lead to
- If successful, this could help explain how GLP-1 drugs reduce cravings and improve weight loss, potentially leading to better treatments for obesity.
- What could go wrong
- This is a small, early-stage observational study with only 50 participants. It measures responses to ads, not long-term weight loss, so results may not apply broadly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLP-1 are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a Weight-Loss drug change how your body handles alcohol?
- Can a diabetes drug improve joint replacement outcomes?
- Pausing GLP-1 drugs before colonoscopy: could a One-Week break improve bowel prep?
- Could a week off GLP-1 drugs make endoscopies safer and more effective?
- Popular diabetes drugs may ease dry eye, study suggests
- Diabetes drug eye risk under microscope